We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
+22.99%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$111M
AUM Growth
-$4.51M
Cap. Flow
-$19M
Cap. Flow %
-17.07%
Top 10 Hldgs %
79.87%
Holding
38
New
7
Increased
5
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$8.37M
2
SGOV icon
iShares 0-3 Month Treasury Bond ETF
SGOV
+$5.52M
3
QNCX icon
Quince Therapeutics
QNCX
+$2.2M
4
PASG icon
Passage Bio
PASG
+$1.7M
5
CALC icon
CalciMedica
CALC
+$388K

Top Sells

Rank Stock Value
1
TLYS icon
Tilly's
TLYS
+$7.07M
2
ANF icon
Abercrombie & Fitch
ANF
+$5.08M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$4.5M
4
IRON icon
Disc Medicine
IRON
+$4.41M
5
EMBK
Embark Technology, Inc. Common Stock
EMBK
+$3.61M

Sector Composition

Rank Sector Weight
1 Healthcare 59.2%
2 Consumer Discretionary 5.18%
3 Technology 2.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CALC icon
26
CalciMedica
CALC
$11.2M
$356K 0.32%
+88,781
New +$388K
TECX
27
Tectonic Therapeutic
TECX
$582M
$243K 0.22%
+21,356
New +$241K
LITS
28
Lite Strategy Inc
LITS
$33.2M
$151K 0.14%
+22,966
New +$146K
IVVD icon
29
Invivyd
IVVD
$185M
$141K 0.13%
+134,696
New +$172K
RAIN
30
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$87.5K 0.08%
+72,926
New +$365K
NGNE icon
31
Neurogene
NGNE
$698M
$19.7K 0.02%
1,187
– –
ACET icon
32
Adicet Bio
ACET
$77.1M
– –
-1,875
Closed -$173K
CARM
33
DELISTED
Carisma Therapeutics
CARM
– –
-411,398
Closed -$1.28M
IRON icon
34
Disc Medicine
IRON
$2.87B
– –
-208,161
Closed -$4.41M
STSA
35
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
– –
-6,440,000
Closed -$4.5M
JNCE
36
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-1,087,961
Closed -$2.01M
MTCR
37
DELISTED
Metacrine, Inc. Common Stock
MTCR
– –
-6,167,458
Closed -$3.52M
EMBK
38
DELISTED
Embark Technology, Inc. Common Stock
EMBK
– –
-1,285,390
Closed -$3.61M
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $156M AUM
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return
PMSA
Patrick M. Sweeney & Associates Libertyville, Illinois $156M AUM 19.16% 1-Year Est. Return
GSWA
Good Steward Wealth Advisors Clarksville, Tennessee $156M AUM 13.06% 1-Year Est. Return

BML Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, BML Capital Management held 38 positions worth $111M, down 3.9% from $116M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

BML Capital Management withdrew a net $19M in Q2 2023, closing 7 positions and reducing 8 holdings. Its most notable exit was Satsuma Pharmaceuticals, Inc. Common Stock, an estimated $4.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 53% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, BML Capital Management opened a new position in Atea Pharmaceuticals worth $8.36M.

  • BML Capital Management's largest Q2 2023 buy was Atea Pharmaceuticals: 2,236,239 shares worth $8.36M.
  • BML Capital Management added most to iShares 0-3 Month Treasury Bond ETF in Q2 2023, an estimated $5.52M increase.
  • BML Capital Management's biggest Q2 2023 reduction was Tilly's, cutting an estimated $7.07M.
  • BML Capital Management fully exited Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2023, selling an estimated $4.5M.
  • BML Capital Management's ten largest holdings make up 80% of its $111M portfolio in Q2 2023.
  • BML Capital Management opened 7 new positions and closed 7 in Q2 2023.
  • BML Capital Management's portfolio value fell 3.9% quarter-over-quarter to $111M.

Based on BML Capital Management's 13F filing for Q2 2023, filed 24 Jul 2023.